Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-AV-1451 PET Imaging in Frontotemporal Dementia
NCT03040713Phase 1Completed
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Apr 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of flortaucipir in frontotemporal dementia (FTD), sponsored by Avid Radiopharmaceuticals. Primary endpoints: Qualitative Evaluation of Flortaucipir PET Scans and Quantitative Evaluation of Flortaucipir PET Scans. Started Apr 2017; status: completed.
02
Drugs
flortaucipir
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT03040713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03040713.